AYTU BioPharma
AYTU
37 hedge funds and large institutions have $10.7M invested in AYTU BioPharma in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
43% more capital inflows, than outflows
Capital inflows: $660K | Capital outflows: $460K
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0.65% less ownership
Funds ownership: 37.02% → 36.37% (-0.65%)
5% less funds holding
Funds holding: 39 → 37 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Crown Advisors Management
Larkspur,
California
|
+$371K |
| 2 |
Diadema Partners
Morristown,
New Jersey
|
+$121K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$54.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.4K |
| 5 |
Persistent Asset Partners
Hong Kong
|
+$34.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FNY Investment Advisers
New York
|
-$80.6K |
| 2 |
DRW Securities
Chicago,
Illinois
|
-$76.4K |
| 3 |
Two Sigma Investments
New York
|
-$70.7K |
| 4 |
Stonepine Capital Management
Bend,
Oregon
|
-$54.8K |
| 5 |
Sentinus LLC
Oak Brook,
Illinois
|
-$52K |
AYTU Hedge Fund Activity: Q1 2026 in Review
37 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2026, worth a combined $10.7M — up 8.7% from $9.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of AYTU and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 8 added.
The largest buyer was Crown Advisors Management, opening a new position worth an estimated $371K. The largest seller was FNY Investment Advisers, cutting an estimated $80.6K.
- 37 institutional investors held AYTU BioPharma (AYTU) as of Q1 2026, down from 39 in Q4 2025.
- Funds reported $10.7M of AYTU BioPharma stock for Q1 2026, up 8.7% quarter-over-quarter.
- 4 funds opened new AYTU BioPharma positions in Q1 2026 and 5 closed out, a net change of -1 holder.
- The largest AYTU BioPharma buyer in Q1 2026 was Crown Advisors Management, an estimated $371K added.
- The largest AYTU BioPharma seller in Q1 2026 was FNY Investment Advisers, an estimated $80.6K sold.
Based on aggregated 13F filings for Q1 2026.